# A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Source: https://onco.cc/trials/nct06478693/  
OnCo record `nct06478693` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of MT-303 run by Myeloid Therapeutics, now recruiting.

## Summary

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC is a phase 1 interventional study registered as NCT06478693 by Myeloid Therapeutics, with 70 participants planned, started 2024-07-01, primary completion expected 2027-12-31. Conditions recorded: Hepatocellular Carcinoma. Interventions recorded: MT-303, MT-303 +Atezolizumab + Bevacizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06478693
- Phase: 1
- Setting: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma
- Sponsor: Myeloid Therapeutics
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT06478693: https://clinicaltrials.gov/study/NCT06478693

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [MT-303](https://onco.cc/drugs/mt-303/)
- companies: [CREATE Medicines](https://onco.cc/companies/create-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct06478693.json